The Latest Breaking News from BioMarin

On Saturday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released new Phase 3 PEGASUS study results on Saturday.

On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.

U.S. health regulators have approved a gene therapy for the most common form of hemophilia

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

BioMarin Pharmaceutical Inc's (NASDAQ:BMRN) Q1 sales reached $519 million, up 7% Y/Y, beating the consensus of $507.52 million. BioMarin said that the increase was achieved "despite continued erosion of the U.S. Kuvan market."  Kuvan is indicated for phenylketonuria. Kuvan still brought in $59.3 million but down from $70.8 million a year ago.…

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million. The decline was attributable to lower sales from Kuvan and Naglazyme, cushioned by higher revenues from Aldurazyme, Vimizim, and Palynziq. Kuvan sales decreased 23% to $ 68.5 million, primarily due…

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that the 

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV)